[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331617-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331617-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plga-peg-crgdfk-kushenol-e-micelles-with-a-therapeutic-potential-for-targeting-ovarian-cancer-research-article","PLGA-PEG-c(RGDfK)-Kushenol E Micelles With a Therapeutic Potential for Targeting Ovarian Cancer - Research Article","","Naturally derived Kushenol E (KE), a poorly soluble autophagy inhibitor, shows strong autophagy-regulating activity in vitro but lacks evidence for antiovarian cancer effects. This study develops cyclic RGDfK-peptide-modified PLGA-PEG-c(RGDfK)-KE micelles (PPCKM) to enhance ovarian tumor targeting and improve drug delivery. PPCKM demonstrates enhanced cumulative release, suitable nanocarrier characteristics, and concentration-dependent anti-tumor activity, promoting apoptosis and suppressing tumor growth in SKOV-3 cell and BALB/c nude mouse xenograft models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plga-peg-crgdfk-kushenol-e-micelles-with-a-therapeutic-potential-for-targeting-ovarian-cancer-research-article/331617/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plga-peg-crgdfk-kushenol-e-micelles-with-a-therapeutic-potential-for-targeting-ovarian-cancer-research-article/331617.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was a nanoparticle micelle system developed for Kushenol E in ovarian cancer?","Question",{"text":63,"@type":64},"KE is poorly soluble and, despite showing autophagy-regulating activity in vitro, had no prior reported antiovarian cancer studies. A PLGA-PEG-c(RGDfK)-based targeting micelle system was designed to improve delivery and tumor targeting.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were PPCKM effects evaluated in the study?",{"text":68,"@type":64},"PPCKM was tested on SKOV-3 cells and in xenograft models using BALB/c nude mice to assess antitumor activity and therapeutic effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What main therapeutic outcomes did PPCKM show?",{"text":72,"@type":64},"PPCKM achieved higher cumulative drug release, supported effective nanocarrier properties, inhibited tumor growth in vivo, suppressed proliferation markers (PCNA and Ki67), and promoted apoptosis through tumor-site targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331617,1790628872,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Wiley  \nIET Nanobiotechnology  \nVolume 2024, Article ID 7136323, 15 pages [https://doi.org/10.1049/nbt2/7136323](https://doi.org/10.1049/nbt2/7136323)  \nResearch Article  \nPLGA-PEG-c(RGDfK)-Kushenol E Micelles With a Therapeutic Potential for Targeting Ovarian Cancer  \nXue Chen , 1 Haopeng Wan , 1 Lijuan Lu ,2 Ran Li ,3 Bo Sun ,4 and Juan Ren 5  \n1Department of Traditional Chinese Medicine, Nanxiang Branch of Ruijin Hospital, Shanghai 201802, China  \n2Department of Gynecology, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215000, China 3School of Pharmacy, Jiangsu University, Zhenjiang 212001, China  \n4Department of Gynecology, Fangta Traditional Chinese Medicine Hospital of Songjiang District of Shanghai, Shanghai 201699, China 5Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine,  \nShanghai University of Traditional Chinese Medicine, Shanghai 200241, China  \nCorrespondence should be addressed to Bo Sun; sunbo_ 524@126.com and Juan Ren; [renjuan312@126.com](renjuan312@126.com)  \nReceived 28 December 2023; Revised 30 September 2024; Accepted 30 October 2024  \nAcademic Editor: Seyed Mohammad Amini  \nCopyright © 2024 Xue Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nBackground: As a naturally derived inhibitor of autophagy, Kushenol E (KE) is a biprenylated flavonoid and is isolated from Sophora flavescens, which has been used for the treatment of cancer, hepatitis, and skin diseases. However, KE, as a poorly soluble drug, exhibited strong autophagy regulating activity in in vitro cancer cell lines, but no related studies have reported its antiovarian cancer property. Therefore, it is very beneficial to enhance the antineoplastic properties of KE by establishing an ovarian tumortargeting nanoparticle system modified with tumor-homing c(RGDfK) peptides.  \nMaterials and Methods: In the current study, poly(lactic-co-glycolic acid)-poly(ethylene glycol)-modified with cyclic RGDfK peptide (PLGA-PEG-c(RGDfK))-KE micelles (PPCKM) were prepared to overcome the poor water solubility of KE to meet the requirement of tumor-active targeting. The effect of PPCKM on ovarian cancer was evaluated on SKOV-3 cells and xenograft models in BALB/c nude mice.  \nResults: The PPCKM showed a higher drug cumulative release ratio (82.16 Æ 7.69% vs. 34.96 Æ 3.05%, at 1.5h) with good morphology, particle size (93.41 Æ 2.84nm), and entrapment efficiency (89.7% Æ 1.3%) . The cell viability, migration, and apoptosis analysis of SKOV-3 cells demonstrated that PPCKM retained potent antitumor effects and promoted apoptosis at early and advanced stages with concentration-dependent. Based on the establishment of xenograft models in BALB/c nude mice, we discovered that PPCKM reduced tumor volume and weight, inhibited proliferating cell nuclear antigen (PCNA) and Ki67 expression, as well as promoted apoptosis by targeting the tumor site.  \nConclusion: The findings in this study suggest that PPCKM may serve as an effective therapeutic option for ovarian cancer.  \nKeywords: c(RGDfK); Kushenol E; ovarian cancer; targeting micelle  \n1. Introduction  \nOvarian cancer is ranked as the third gynecological cancer in terms of frequency after cancer of the cervix and uterine but has the highest death rate [1]. The 5-year survival rate of the disease is roughly 47%[2] . A total of 313,959 new cases of the disease were recorded globally in 2020, with the agestandardized rates of incidence of ovarian cancer being 6.6 per 100,000 [3] . Characteristics of the disease include poor prognosis, late-stage presentation, and high mortality rates.  \nThe high ovarian cancer mortality rate is driven by factors such as diagnosis of the disease in the advanced stage of the disease because of lack of proper screening tests, delayed onset of sym","cbCaiebAJMtLnIqM","https://ap.wps.com/l/cbCaiebAJMtLnIqM","pdf",7381360,15,"English","# Introduction\n# Materials and Methods\n# Results\n# Conclusion","[{\"question\":\"Why was a nanoparticle micelle system developed for Kushenol E in ovarian cancer?\",\"answer\":\"KE is poorly soluble and, despite showing autophagy-regulating activity in vitro, had no prior reported antiovarian cancer studies. A PLGA-PEG-c(RGDfK)-based targeting micelle system was designed to improve delivery and tumor targeting.\"},{\"question\":\"How were PPCKM effects evaluated in the study?\",\"answer\":\"PPCKM was tested on SKOV-3 cells and in xenograft models using BALB/c nude mice to assess antitumor activity and therapeutic effects.\"},{\"question\":\"What main therapeutic outcomes did PPCKM show?\",\"answer\":\"PPCKM achieved higher cumulative drug release, supported effective nanocarrier properties, inhibited tumor growth in vivo, suppressed proliferation markers (PCNA and Ki67), and promoted apoptosis through tumor-site targeting.\"}]","PLGA-PEG-c(RGDfK)-Kushenol E Micelles With a Therapeutic Potential for Targeting Ovarian Cancer - Research Article | PDF",1789994328,38]